Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors

Figures

• 

  Fig. 1. Study flow chart of the patients enrolled. CTEPH chronic thromboembolic pulmonary hypertension.

• 

  Fig. 2. Heparin-calibrated anti-factor Xa activity in all 50 patients. (a) Comparison between trough and peak. (b) Comparison between rivaroxaban, apixaban, and edoxaban at trough and peak. (c) Comparison between reduced-dosage factor Xa inhibitor and reference-dosage factor Xa inhibitor. AXA anti-factor Xa activity.

• 

  Fig. 3. (a) Plasma concentration of rivaroxaban at peak and trough. (b) Correlation of heparin-calibrated anti-factor Xa activity and plasma concentration of rivaroxaban. AXA anti-factor Xa activity.

• 

  Fig. 4. (a) Plasma concentration of apixaban at peak and trough. (b) Correlation of heparin-calibrated anti-factor Xa activity and plasma concentration of apixaban. AXA anti-factor Xa activity.

• 

  Fig. 5. Correlation of creatinine clearance and heparin-calibrated anti-factor Xa activity: (a) at peak for all factor Xa inhibitors; (b) at trough of once-daily factor Xa inhibitor (rivaroxaban, and edoxaban); (c) at trough of twice-daily factor Xa inhibitor (apixaban). AXA anti-factor Xa activity, BID twice daily, CrCl creatinine clearance, QD once daily.

• 

  Fig. 6. Relationship between heparin-calibrated anti-factor Xa activity and bleeding events: (a) receiver-operating characteristic curve analysis for major and non-major clinically relevant bleeding events using peak heparin-calibrated anti-factor Xa activity, (b) Kaplan–Meier analysis of major and non-major clinically relevant bleeding events. AUC area under curve, AXA anti-factor Xa activity, CI confidence intervals, HR hazard ratio, ROC receiver operating characteristic. *Multivariate cox proportional-hazards model adjusted by age and presence of invasive treatment.